AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32493448 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin A supplementation
Number of subjects: 62
Study 32493484 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylation at 15 cytosine-(phosphate)-guanine sites (CpGs)
Number of subjects: 301
Study 32493484 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylation at four (26.7%) CpG sites
Number of subjects: 301
Study 32493484 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased methylation at cg06155341
Number of subjects: 301
Study 32493484 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylation changes related to maternal underweight, preeclampsia, and adult type 2 diabetes
Number of subjects: 301
Study 32493508 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimble suction device
Number of subjects: 60
Study 32493508 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutometer
Number of subjects: 60
Study 32493508 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimble and Cutometer suction devices
Number of subjects: 60
Study 32493977 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based strength and endurance training program (12 weeks pre and 20 weeks post ahSC transplant)
Number of subjects: 6
Study 32494819 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipsilateral arm movement
Number of subjects: 2
Study 32494819 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral arm movement
Number of subjects: 2
Study 32494819 — intervention group
Group type: EXPERIMENTAL
Intervention: Grasping
Number of subjects: 2
Study 32495011 — intervention group
Group type: EXPERIMENTAL
Intervention: 1TCM model
Number of subjects: 0
Study 32495282 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastectomy
Number of subjects: 100
Study 32495282 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumpectomy
Number of subjects: 100
Study 32495282 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage 0 patients (N=6)
Number of subjects: 100
Study 32495282 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage III patients (N=6)
Number of subjects: 100
Study 32495282 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage I patients (N=25)
Number of subjects: 100
Study 32495282 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage II patients (N=16)
Number of subjects: 100
Study 32495282 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfaction with Decision
Number of subjects: 100
Study 32495282 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision Regret
Number of subjects: 100
Study 32495282 — intervention group
Group type: EXPERIMENTAL
Intervention: FACT-B quality of life
Number of subjects: 100
Study 32495314 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face EEG training program followed by e-learning sessions at day 1, day 15, day 30, and day 90.
Number of subjects: 250
Study 32495314 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face EEG training program supplemented with e-learning.
Number of subjects: 250
Study 32496194 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity-dependent modulation in neurogliaform cells
Number of subjects: 0
Study 32496203 — intervention group
Group type: EXPERIMENTAL
Intervention: mROAD intervention (SMS text message-based program)
Number of subjects: 72
Study 32496203 — intervention group
Group type: COMPARATOR
Intervention: Sham control group (daily sham text messages)
Number of subjects: 72
Study 32496206 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-assessment web application users with anosmia (n=127,586)
Number of subjects: 3799535
Study 32496206 — intervention group
Group type: COMPARATOR
Intervention: Self-assessment web application users without anosmia (n=1,597,289)
Number of subjects: 3799535
Study 32496206 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with anosmia
Number of subjects: 3799535
Study 32496206 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with fever and/or cough
Number of subjects: 3799535
Study 32496401 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural processing of health information
Number of subjects: 24
Study 32496541 — intervention group
Group type: EXPERIMENTAL
Intervention: Time from diagnosis to treatment (TDT) of 0 to 5 days
Number of subjects: 2263
Study 32496541 — intervention group
Group type: EXPERIMENTAL
Intervention: Time from diagnosis to treatment (TDT) of 6 to 10 days
Number of subjects: 2263
Study 32496541 — intervention group
Group type: EXPERIMENTAL
Intervention: Time from diagnosis to treatment (TDT) of 11 to 15 days
Number of subjects: 2263
Study 32496541 — intervention group
Group type: EXPERIMENTAL
Intervention: Time from diagnosis to treatment (TDT) of >15 days
Number of subjects: 2263
Study 32496541 — intervention group
Group type: EXPERIMENTAL
Intervention: TDT as a continuous variable
Number of subjects: 2263
Study 32496557 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-infrared photoimmunotherapy (NIR-PIT) using RM1929/ASP1929 (anti-EGFR antibody plus IRDye700DX)
Number of subjects: 0
Study 32496557 — intervention group
Group type: EXPERIMENTAL
Intervention: NIR-PIT
Number of subjects: 0
Study 32496966 — intervention group
Group type: EXPERIMENTAL
Intervention: technology-based physical activity intervention
Number of subjects: 0
Study 32497016 — intervention group
Group type: EXPERIMENTAL
Intervention: Online dissemination of the HIV-testing advice
Number of subjects: 0
Study 32497016 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissemination with additional group-level training
Number of subjects: 0
Study 32497016 — intervention group
Group type: COMPARATOR
Intervention: Control condition with no intervention
Number of subjects: 0
Study 32497016 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation fidelity and feasibility assessment through surveys and interviews
Number of subjects: 0
Study 32497409 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly prophylaxis (WP)
Number of subjects: 120
Study 32497409 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized interval prophylaxis (IP)
Number of subjects: 120
Study 32497409 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified prophylaxis or episodic treatment
Number of subjects: 120
Study 32497440 — intervention group
Group type: EXPERIMENTAL
Intervention: Repository corticotropin injection (RCI, Acthar® Gel) as adjunctive therapy along with DMARDs and glucocorticoids
Number of subjects: 0
Study 32497440 — intervention group
Group type: COMPARATOR
Intervention: DMARDs and glucocorticoids alone (control group)
Number of subjects: 0
Study 32497499 — intervention group
Group type: EXPERIMENTAL
Intervention: T cells from human bladder tumors and non-malignant tissue
Number of subjects: 7
Study 32497499 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-cell RNA and paired T cell receptor (TCR) sequencing
Number of subjects: 7
Study 32497600 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor postural control
Number of subjects: 504
Study 32497600 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate postural control
Number of subjects: 504
Study 32497600 — intervention group
Group type: EXPERIMENTAL
Intervention: Using a walking aid in the acute phase
Number of subjects: 504
Study 32497600 — intervention group
Group type: EXPERIMENTAL
Intervention: Fall at the stroke unit
Number of subjects: 504
Study 32497600 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent falls
Number of subjects: 504
Study 32498033 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab (12 mg/day on 5 consecutive days at baseline and on 3 consecutive days 12 months later)
Number of subjects: 972
Study 32498033 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab (12 mg/day on 3 days; ≥12 months apart)
Number of subjects: 972
Study 32498033 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab exposure timing
Number of subjects: 972
Study 32498033 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab exposure and autoimmune thyroid adverse events
Number of subjects: 972
Study 32498033 — intervention group
Group type: EXPERIMENTAL
Intervention: Annualized relapse rate post alemtuzumab
Number of subjects: 972
Study 32498100 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic full-thickness resection (eFTR)
Number of subjects: 367
Study 32498621 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 Diabetes Mellitus (T2D)
Number of subjects: 411
Study 32498621 — intervention group
Group type: COMPARATOR
Intervention: Normal-weight and obese controls without diabetes mellitus
Number of subjects: 411
Study 32499013 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased alpha power
Number of subjects: 70
Study 32499013 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased alpha band connectivity
Number of subjects: 70
Study 32499013 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired structural connectivity (increased radial diffusivity)
Number of subjects: 70
Study 32499013 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontal slow-wave activity (SWA)
Number of subjects: 70
Study 32499013 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in connectivity
Number of subjects: 70
Study 32499089 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing care procedures (NCP)
Number of subjects: 340
Study 32499241 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-myeloablative conditioning regimen (low-dose total body irradiation +/- fludarabine or clofarabine) followed by mycophenolate mofetil and a calcineurin inhibitor ± sirolimus
Number of subjects: 1720
Study 32499275 — intervention group
Group type: EXPERIMENTAL
Intervention: Panenteric capsule endoscopy (CE)
Number of subjects: 99
Study 32499275 — intervention group
Group type: COMPARATOR
Intervention: Magnetic resonance enterography (MRE) and/or ileocolonoscopy (IC)
Number of subjects: 99
Study 32499275 — intervention group
Group type: COMPARATOR
Intervention: Magnetic resonance enterography (MRE)
Number of subjects: 99
Study 32499329 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraocular pressure (IOP) measured with an implanted intraocular telemetry sensor
Number of subjects: 22
Study 32499388 — intervention group
Group type: EXPERIMENTAL
Intervention: Child-reported PCSI
Number of subjects: 0
Study 32499388 — intervention group
Group type: COMPARATOR
Intervention: Parent-reported PCSI
Number of subjects: 0
Study 32499388 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall parent-child agreement
Number of subjects: 0
Study 32499388 — intervention group
Group type: EXPERIMENTAL
Intervention: Postinjury ratings
Number of subjects: 0
Study 32499388 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical symptoms
Number of subjects: 0
Study 32499388 — intervention group
Group type: EXPERIMENTAL
Intervention: Older children
Number of subjects: 0
Study 32499730 — intervention group
Group type: EXPERIMENTAL
Intervention: Theta-burst stimulation (TBS) administered for 6 weeks (5 days a week for the first 3 weeks, then 2 days a week for the next 3 weeks) in the dorsolateral prefrontal cortex.
Number of subjects: 90
Study 32499730 — intervention group
Group type: COMPARATOR
Intervention: Sham control (not explicitly detailed in the abstract).
Number of subjects: 90
Study 32500206 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin
Number of subjects: 0
Study 32500206 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Number of subjects: 0
Study 32500206 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel
Number of subjects: 0
Study 32500206 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin and Cyclophosphamide (AC)
Number of subjects: 0
Study 32500206 — intervention group
Group type: COMPARATOR
Intervention: Combined Paclitaxel and Carboplatin
Number of subjects: 0
Study 32500294 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate plus prednisone or prednisolone
Number of subjects: 1874
Study 32500294 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 1874
Study 32500294 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 1874
Study 32500294 — intervention group
Group type: COMPARATOR
Intervention: Overall population
Number of subjects: 1874
Study 32500374 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D gait analysis during free treadmill walking in people with MS
Number of subjects: 35
Study 32500374 — intervention group
Group type: COMPARATOR
Intervention: 3D gait analysis during free treadmill walking in healthy controls
Number of subjects: 35
Study 32500515 — intervention group
Group type: EXPERIMENTAL
Intervention: Panda-Nerve Block app
Number of subjects: 29
Study 32500620 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular autologous bone marrow aspirate (BMA) injections
Number of subjects: 10
Study 32501274 — intervention group
Group type: COMPARATOR
Intervention: Black/African American-focused campaign
Number of subjects: 0
Study 32501274 — intervention group
Group type: COMPARATOR
Intervention: Hispanic/Latino-focused campaign
Number of subjects: 0
Study 32501274 — intervention group
Group type: COMPARATOR
Intervention: Black/African American-focused campaign post-scandal
Number of subjects: 0
Study 32501274 — intervention group
Group type: COMPARATOR
Intervention: Hispanic/Latino-focused campaign post-scandal
Number of subjects: 0
Study 32501275 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergame intervention study
Number of subjects: 1632
Study 32501454 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose anakinra (5 mg/kg twice a day intravenously)
Number of subjects: 45
Study 32501454 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (200 mg hydroxychloroquine twice a day and 400 mg lopinavir with 100 mg ritonavir twice a day)
Number of subjects: 45
Study 32501528 — intervention group
Group type: EXPERIMENTAL
Intervention: Filanesib in combination with pomalidomide and dexamethasone
Number of subjects: 47
Study 32501528 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 47
Study 32501595 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 10680
Study 32501945 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with DSPN
Number of subjects: 48
Study 32502219 — intervention group
Group type: EXPERIMENTAL
Intervention: United Nations Istanbul Protocol (UNIP)
Number of subjects: 20
Study 32502219 — intervention group
Group type: EXPERIMENTAL
Intervention: Validated pain screen (Brief Pain Inventory-Short Form [BPISF])
Number of subjects: 20
Study 32502219 — intervention group
Group type: COMPARATOR
Intervention: Reference standard (pain specialist evaluation)
Number of subjects: 20
Study 32502267 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg twice daily
Number of subjects: 624
Study 32502272 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted recombinant zoster vaccine (RZV) - 2 initial doses
Number of subjects: 70
Study 32502272 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted recombinant zoster vaccine (RZV) - 1 additional dose
Number of subjects: 70
Study 32502272 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted recombinant zoster vaccine (RZV) - 2 additional doses
Number of subjects: 70
Study 32502277 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D deficiency (25(OH)D <50 nmol/l)
Number of subjects: 1382
Study 32502277 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe vitamin D deficiency (25(OH)D <25 nmol/l)
Number of subjects: 1382
Study 32502277 — intervention group
Group type: EXPERIMENTAL
Intervention: Low 25(OH)D serum level
Number of subjects: 1382
Study 32502277 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D levels (seasonal influence)
Number of subjects: 1382
Study 32502277 — intervention group
Group type: EXPERIMENTAL
Intervention: High BMI and dark-skinned ethnicities
Number of subjects: 1382
Study 32502277 — intervention group
Group type: EXPERIMENTAL
Intervention: 25(OH)D serum level
Number of subjects: 1382
Study 32502336 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 1895344
Number of subjects: 0
Study 32502439 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery
Number of subjects: 0
Study 32502439 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 32502506 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (Carboplatin/etoposide and cyclophosphamide/etoposide regimens, 4 cycles every 3 weeks) followed by radiation therapy (RT)
Number of subjects: 41
Study 32502506 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy (18 Gy craniospinal RT for metastatic tumors, whole brain RT for basal ganglia tumors, or whole ventricular RT followed by 12.6 Gy boost RT)
Number of subjects: 41
Study 32502854 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased nasal resistance (measured by 4-phase rhinomanometry)
Number of subjects: 126
Study 32503441 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline assessment including self-administered PA and ST questionnaires and standardized measurement of blood pressure, waist circumference, and blood parameters; no treatment or intervention after 5 weeks
Number of subjects: 175
Study 32503469 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab and entinostat (2 mg/m2)
Number of subjects: 0
Study 32503476 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive performance assessment using a broad neuropsychological test battery
Number of subjects: 1
Study 32503548 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-item version of the Lee Fatigue Scale (LFS)
Number of subjects: 525
Study 32503548 — intervention group
Group type: COMPARATOR
Intervention: 5-item version of the Lee Fatigue Scale (LFS)
Number of subjects: 525
Study 32503583 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of care (QoC) indicators in ICU
Number of subjects: 396
Study 32503583 — intervention group
Group type: COMPARATOR
Intervention: Ventilated ICU patients
Number of subjects: 396
Study 32503583 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 396
Study 32503811 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical compression therapy (classes I and II)
Number of subjects: 94
Study 32503866 — intervention group
Group type: EXPERIMENTAL
Intervention: TeGeCoach - a 12-month home-based exercise programme consisting of telemonitored intermittent walking exercise with medical supervision and telephone health coaching.
Number of subjects: 1760
Study 32503866 — intervention group
Group type: COMPARATOR
Intervention: Usual care - information leaflets and access to supervised exercise programmes, physical therapy, and healthy lifestyle programmes.
Number of subjects: 1760
Study 32503866 — intervention group
Group type: EXPERIMENTAL
Intervention: TeGeCoach
Number of subjects: 1760
Study 32503866 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1760
Study 32503869 — intervention group
Group type: COMPARATOR
Intervention: False-positive group
Number of subjects: 130
Study 32503869 — intervention group
Group type: COMPARATOR
Intervention: True-positive group
Number of subjects: 130
Study 32503869 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 130
Study 32503947 — intervention group
Group type: EXPERIMENTAL
Intervention: murlentamab treatment
Number of subjects: 28
Study 32503950 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab and Ipilimumab combination therapy
Number of subjects: 4
Study 32504089 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-γ Release Assay
Number of subjects: 0
Study 32504219 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line treatment
Number of subjects: 1806
Study 32504369 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtotal gastrectomy with Billroth II reconstruction (SGB2)
Number of subjects: 14
Study 32504369 — intervention group
Group type: COMPARATOR
Intervention: Nongastrectomized in-house relatives (Control)
Number of subjects: 14
Study 32504533 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound activity index consisting of bowel wall thickness and colour Doppler
Number of subjects: 164
Study 32504533 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound activity index
Number of subjects: 164
Study 32504550 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib
Number of subjects: 0
Study 32504550 — intervention group
Group type: COMPARATOR
Intervention: [sorafenib + vorinostat]
Number of subjects: 0
Study 32504550 — intervention group
Group type: COMPARATOR
Intervention: Neratinib alone
Number of subjects: 0
Study 32504883 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting (prolonged fast from 18.00 h to 20.00 h the next day)
Number of subjects: 23
Study 32504883 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting
Number of subjects: 23
Study 32505869 — intervention group
Group type: EXPERIMENTAL
Intervention: c-FLOW (Ornim Medical) monitoring
Number of subjects: 21
Study 32506182 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI (Percutaneous Coronary Intervention)
Number of subjects: 364
Study 32506182 — intervention group
Group type: EXPERIMENTAL
Intervention: PS1 (high resting coronary flow, dominantly LAD lesions)
Number of subjects: 364
Study 32506182 — intervention group
Group type: EXPERIMENTAL
Intervention: PS3 (non-LAD lesions with low hyperemic Pd)
Number of subjects: 364
Study 32506203 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous recordings of ambient sound using a smartphone to track auditory signatures of breaths
Number of subjects: 50
Study 32506317 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily (BID), with adjustments to 10 mg BID permitted post-month 1.
Number of subjects: 686
Study 32506317 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID, with adjustments to 10 mg BID permitted post-month 1.
Number of subjects: 686
Study 32506358 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromuscular stimulation (EMS) for wrist flexors on nonparetic limb, 30 sessions for 6 weeks (60 min/session, 30 min EMS)
Number of subjects: 30
Study 32506358 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS) for nonparetic limb, 30 sessions for 6 weeks (60 min/session, 30 min TENS)
Number of subjects: 30
Study 32506369 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal trastuzumab
Number of subjects: 34
Study 32506428 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive model 1 (logistic regression)
Number of subjects: 1002
Study 32506428 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive model 2 (logistic regression)
Number of subjects: 1002
Study 32506428 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive model 3 (logistic regression)
Number of subjects: 1002